As injectable weight-loss medicines become more popular, healthcare professionals are reminding South Africans that where a medicine comes from can be just as important as what's inside it.
Growing public interest in injectable weight-loss medicines, including semaglutide products, has highlighted the importance of patient awareness, appropriate medical oversight and the use of medicines supplied through the formal regulatory framework.
Recent regulatory concerns in South Africa have drawn attention to the potential risks associated with unregistered or improperly supplied GLP-1/GIP injectable products, particularly where patients may not have clarity on a product’s origin, quality controls or appropriate use.
The issue is broader than any single supplier or product. For patients, the key consideration is whether a medicine has been reviewed by the appropriate authorities and is prescribed, dispensed and monitored through recognised healthcare channels.
The growing demand for these treatments has also created confusion for some consumers, particularly when products are promoted online or through wellness channels as easier or lower-cost alternatives to registered medicines.
